Proteolysis in Colorectal Cancer

Overview

Journal Mol Pathol

Specialty Molecular Biology

Date 2000 Jan 6

PMID 10621835

Citations 7

Authors

E A Garbett

M W Reed

N J Brown

Affiliations

Soon will be listed here.

Abstract

Background: The process of metastasis is complex, involving many interrelated stages, including proteolysis. Proteolysis occurs in both normal and pathological processes and involves the breakdown of the extracellular matrix and/or basement membrane by proteolytic enzymes. Normally, proteolysis is tightly controlled by specific endogenous proteinase inhibitors. However, in certain disease processes, including cancer, controlled but abnormal proteolysis seems to occur. Proteinases involved in tumour invasion and metastasis include the matrix metalloproteinases (MMPs) and the serine proteinases.

Aims: To gain a greater understanding of the proteolytic process occurring in colorectal cancer and to determine which, if any, proteinases are upregulated.

Methods: The synthesis of proteinases and their inhibitors was compared in paired tumour and normal tissue samples from patients with colorectal cancer (n = 24). Substrate zymography was used to determine the synthesis of MMPs (MMP-2, MMP-9, and MMP-3) and the plasminogen activators (urokinase and tissue-type plasminogen activators); enzyme linked immunosorbent assays (ELISAs) were used to determine the concentrations of MMP-1 and tissue inhibitor of metalloproteinase 1 (TIMP-1); and the technique of quenched fluorescence substrate hydrolysis was performed to determine the total MMP activity of each sample.

Results: In general, both proteinase and inhibitor expression was greater in the tumour tissue when compared with the corresponding normal colorectal tissue. The amount of active MMPs was greater in the tumour tissue.

Conclusions: The increased extracellular proteinase concentrations and activity may encourage tumour invasion and metastasis. This study points to MMP-9 as being of potential major importance in the development of this form of cancer.

Citing Articles

Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness.

Weiswald L, Richon S, Validire P, Briffod M, Lai-Kuen R, Cordelieres F Br J Cancer. 2009; 101(3):473-82.

PMID: 19603013 PMC: 2720229. DOI: 10.1038/sj.bjc.6605173.

Peroxisome proliferator-activated receptor gamma agonists inhibit the proliferation and invasion of human colon cancer cells.

Shen D, Deng C, Zhang M Postgrad Med J. 2007; 83(980):414-9.

PMID: 17551074 PMC: 2600042. DOI: 10.1136/pmj.2006.052761.

Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas.

Sun X, Zhang H Mol Cancer. 2006; 5:43.

PMID: 17026740 PMC: 1618857. DOI: 10.1186/1476-4598-5-43.

Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry.

Engwegen J, Helgason H, Cats A, Harris N, Bonfrer J, Schellens J World J Gastroenterol. 2006; 12(10):1536-44.

PMID: 16570345 PMC: 4124285. DOI: 10.3748/wjg.v12.i10.1536.

Significance and prognostic value of lysosomal enzyme activities measured in surgically operated adenocarcinomas of the gastroesophageal junction and squamous cell carcinomas of the lower third of esophagus.

Altorjay A, Paal B, Sohar N, Kiss J, Szanto I, Sohar I World J Gastroenterol. 2005; 11(37):5751-6.

PMID: 16270380 PMC: 4479671. DOI: 10.3748/wjg.v11.i37.5751.

References

Zeng Z, Guillem J . Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases. Br J Cancer. 1995; 72(3):575-82. PMC: 2033901. DOI: 10.1038/bjc.1995.376. View

Matrisian L, Wright J, Newell K, Witty J . Matrix-degrading metalloproteinases in tumor progression. Princess Takamatsu Symp. 1994; 24:152-61. View

Zeng Z, Huang Y, Cohen A, Guillem J . Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol. 1996; 14(12):3133-40. DOI: 10.1200/JCO.1996.14.12.3133. View

Ring P, Johansson K, Hoyhtya M, Rubin K, Lindmark G . Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer--a predictor of tumour stage. Br J Cancer. 1997; 76(6):805-11. PMC: 2228035. DOI: 10.1038/bjc.1997.466. View

Pyke C, Kristensen P, Ralfkiaer E, Eriksen J, Blasi F, Dano K . Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol. 1991; 138(5):1059-67. PMC: 1886028. View

Knight C, Willenbrock F, Murphy G . A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992; 296(3):263-6. DOI: 10.1016/0014-5793(92)80300-6. View

Duffy M, OGrady P, Devaney D, OSiorain L, Fennelly J, Lijnen H . Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res. 1988; 48(5):1348-9. View

Yoshimoto M, Itoh F, Yamamoto H, Hinoda Y, Imai K, YACHI A . Expression of MMP-7(PUMP-1) mRNA in human colorectal cancers. Int J Cancer. 1993; 54(4):614-8. DOI: 10.1002/ijc.2910540415. View

Buo L, Meling G, Karlsrud T, Johansen H, Aasen A . Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Hum Pathol. 1995; 26(10):1133-8. DOI: 10.1016/0046-8177(95)90276-7. View

10.

Seftor R . Electrophoretic analysis of proteins associated with tumor cell invasion. Electrophoresis. 1994; 15(3-4):454-62. DOI: 10.1002/elps.1150150162. View

11.

Yu A, Hewitt R, Connor E, Stetler-Stevenson W . Matrix metalloproteinases. Novel targets for directed cancer therapy. Drugs Aging. 1997; 11(3):229-44. DOI: 10.2165/00002512-199711030-00006. View

12.

Hewitt R, Leach I, Powe D, Clark I, Cawston T, Turner D . Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer. 1991; 49(5):666-72. DOI: 10.1002/ijc.2910490507. View

13.

Murashige M, Miyahara M, Shiraishi N, Saito T, Kohno K, Kobayashi M . Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors. Jpn J Clin Oncol. 1996; 26(5):303-9. DOI: 10.1093/oxfordjournals.jjco.a023237. View

14.

Kwaan H . The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev. 1992; 11(3-4):291-311. DOI: 10.1007/BF01307184. View

15.

Liotta L, Steeg P, Stetler-Stevenson W . Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991; 64(2):327-36. DOI: 10.1016/0092-8674(91)90642-c. View

16.

Ralfkiaer E, Kirkeby L, Kristensen P, Lund L, Dano K . Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol. 1991; 138(1):111-7. PMC: 1886060. View

17.

Gallegos N, Smales C, Savage F, Hembry R, Boulos P . The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer. Surg Oncol. 1995; 4(2):111-9. DOI: 10.1016/s0960-7404(10)80015-5. View

18.

Brown C, Rahman S, Morton A, Beauchamp C, Bramwell H, Buttle D . Inhibitors of collagenase but not of gelatinase reduce cartilage explant proteoglycan breakdown despite only low levels of matrix metalloproteinase activity. Clin Mol Pathol. 1996; 49(6):M331-9. PMC: 408083. DOI: 10.1136/mp.49.6.m331. View

19.

Baici A, STRAULI P . Extracellular cysteine proteinase and collagenase activities as a consequence of tumor-host interaction in the rabbit V2 carcinoma. Invasion Metastasis. 1984; 4(1):13-27. View

20.

Gelister J, Mahmoud M, Lewin M, Gaffney P, Boulos P . Plasminogen activators in human colorectal neoplasia. Br Med J (Clin Res Ed). 1986; 293(6549):728-31. PMC: 1341448. DOI: 10.1136/bmj.293.6549.728. View